ProCE Banner Activity

Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

Multimedia

Watch this on-demand Webcast capturing a live CCO Webinar of global experts discussing how they currently use PARP inhibitors to treat ovarian cancer, providing a look ahead at new data and promising agents that may soon change practice.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: February 11, 2021

Expiration: February 10, 2022

Share

Faculty

Antonio Gonzalez-Martin

Antonio Gonzalez-Martin, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Learning Objectives

  • Assess the improvement in risk of progression from the addition of PARP inhibitors in frontline treatment and how maintenance therapy can affect that
  • Discuss patient and tumor characteristics that identify candidates for treatment with frontline PARP inhibitors
  • Describe the differences among the PARPi regarding dosing, administration, adverse events, and overall properties

Faculty Disclosure

Primary Author

Antonio Gonzalez-Martin, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain

Antonio González-Martin, MD, has disclosed that he has received consulting fees from AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp & Dohme, Mersana, and Roche.

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees and other financial or material support from Merck.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Elevar Therapeutics, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp & Dohme, Oncoinvent; and contracted research from Genmab and Hoffmann-La Roche.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.